Royalty Pharma (RPRX) Stock Price Target 2026

The average analyst price target for Royalty Pharma is $56.80, 16.7% below the current price. Of 7 analysts, 7 rate it Buy. Targets range from $38 to $78. The latest change came on Nov 5, 2026, when Citigroup raised its price target on Royalty Pharma from $70 to $78 and kept a Buy rating.

The Average Analyst Price Target for Royalty Pharma is $56.80.

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$56.80Upside to Avg. PT-16.7%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Royalty Pharma Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 5, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$70→$78
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$65→$67
Sep 8, 2026	TD Cowen	Michael Nedelcovych	PT Raise	Buy	$65→$68
Aug 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$58→$62
Jul 13, 2026	TD Cowen	Steve Scala	PT Raise	Buy	$50→$65
May 7, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$50→$66
May 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$50→$58
Apr 21, 2026	UBS	Ashwani Verma	PT Raise	Buy	$51→$57
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$61→$63
Jan 30, 2026	UBS	Ashwani Verma	Upgrade	Neutral→Buy	$38→$49
Jan 27, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$48→$50
Dec 11, 2025	TD Cowen	Steve Scala	PT Raise	Buy	$42→$45
Oct 10, 2025	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$55→$54
Sep 30, 2025	Goldman Sachs	Asad Haider	Initiate	Buy	$42
Jul 22, 2025	Citigroup	Geoff Meacham	PT Raise	Buy	$40→$42
Jul 10, 2025	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$51→$54
Oct 25, 2024	Citigroup	Andrew Baum	PT Cut	Buy	$60→$40
Aug 14, 2024	Goldman Sachs	Chris Shibutani	PT Raise	Buy	$50→$51
Jul 11, 2024	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$48→$51
Jun 3, 2024	UBS	Ashwani Verma	Downgrade	Buy→Neutral	$28